title: Targeting melanoma by small molecules: challenges ahead.
abstract: Significant progress has been made in targeting melanoma using small molecule inhibitors, but challenges remain. Here we describe the history of screening approaches in melanoma and their limitations. We propose several approaches to refine our screening models to enhance the discovery process. It is hoped that this discussion will stimulate further improvements in our development of small molecules inhibitors for treatment of melanoma patients.
authors.affiliation: Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Rizwan
authors.initials: R
authors.lastname: Haq
authors.forename: David E
authors.initials: DE
authors.lastname: Fisher
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry; D045744:Cell Line, Tumor; D004249:DNA Damage; D016503:Drug Delivery Systems; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007211:Indoles / Q000737:chemistry; D008545:Melanoma / Q000503:physiopathology* / Q000628:therapy*; D051379:Mice; D010316:Particle Size; D010455:Peptides / Q000737:chemistry; D015398:Signal Transduction; D013449:Sulfonamides / Q000737:chemistry; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D010455:Peptides; D013449:Sulfonamides; D000077484:Vemurafenib